Endogenous Zinc-Ion-Triggered In Situ Gelation Enables Zn Capture to Reprogram Benign Hyperplastic Prostate Microenvironment and Shrink Prostate
© 2023 Wiley-VCH GmbH..
Benign prostatic hyperplasia (BPH) as the leading cause of urination disorder is still a refractory disease, and there have no satisfied drugs or treatment protocols yet. With identifying excessive Zn2+ , inflammation, and oxidative stress as the etiology of aberrant hyperplasia, an injectable sodium alginate (SA) and glycyrrhizic acid (GA)-interconnected hydrogels (SAGA) featuring Zn2+ -triggered in situ gelation are developed to load lonidamine for reprogramming prostate microenvironment and treating BPH. Herein, SAGA hydrogels can crosslink with Zn2+ in BPH via coordination chelation and switch free Zn2+ to bound ones, consequently alleviating Zn2+ -arisen inflammation and glycolysis. Beyond capturing Zn2+ , GA with intrinsic immunoregulatory property can also alleviate local inflammation and scavenge reactive oxygen species (ROS). Intriguingly, Zn2+ chelation-bridged interconnection in SAGA enhances its mechanical property and regulates the degradation rate to enable continuous lonidamine release, favoring hyperplastic acini apoptosis and further inhibiting glycolysis. These multiple actions cooperatively reprogram BPH microenvironment to alleviate characteristic symptoms of BPH and shrink prostate. RNA sequencing reveals that chemotaxis, glycolysis, and tumor necrosis factor (TNF) inflammation-related pathways associated with M1-like phenotype polarization are discerned as the action rationales of such endogenous Zn2+ -triggered in situ hydrogels, providing a candidate avenue to treat BPH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Advanced materials (Deerfield Beach, Fla.) - 36(2024), 11 vom: 01. März, Seite e2307796 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ge, Jianchao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benign prostatic hyperplasia |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/adma.202307796 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365875570 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365875570 | ||
| 003 | DE-627 | ||
| 005 | 20240315232945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/adma.202307796 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM365875570 | ||
| 035 | |a (NLM)38096869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ge, Jianchao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endogenous Zinc-Ion-Triggered In Situ Gelation Enables Zn Capture to Reprogram Benign Hyperplastic Prostate Microenvironment and Shrink Prostate |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Benign prostatic hyperplasia (BPH) as the leading cause of urination disorder is still a refractory disease, and there have no satisfied drugs or treatment protocols yet. With identifying excessive Zn2+ , inflammation, and oxidative stress as the etiology of aberrant hyperplasia, an injectable sodium alginate (SA) and glycyrrhizic acid (GA)-interconnected hydrogels (SAGA) featuring Zn2+ -triggered in situ gelation are developed to load lonidamine for reprogramming prostate microenvironment and treating BPH. Herein, SAGA hydrogels can crosslink with Zn2+ in BPH via coordination chelation and switch free Zn2+ to bound ones, consequently alleviating Zn2+ -arisen inflammation and glycolysis. Beyond capturing Zn2+ , GA with intrinsic immunoregulatory property can also alleviate local inflammation and scavenge reactive oxygen species (ROS). Intriguingly, Zn2+ chelation-bridged interconnection in SAGA enhances its mechanical property and regulates the degradation rate to enable continuous lonidamine release, favoring hyperplastic acini apoptosis and further inhibiting glycolysis. These multiple actions cooperatively reprogram BPH microenvironment to alleviate characteristic symptoms of BPH and shrink prostate. RNA sequencing reveals that chemotaxis, glycolysis, and tumor necrosis factor (TNF) inflammation-related pathways associated with M1-like phenotype polarization are discerned as the action rationales of such endogenous Zn2+ -triggered in situ hydrogels, providing a candidate avenue to treat BPH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Zn2+-crosslinked in situ gelation | |
| 650 | 4 | |a benign prostatic hyperplasia | |
| 650 | 4 | |a endogenous Zn2+ capture | |
| 650 | 4 | |a glycolysis inhibition | |
| 650 | 4 | |a inflammation microenvironment reprogramming | |
| 650 | 7 | |a Zinc |2 NLM | |
| 650 | 7 | |a J41CSQ7QDS |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 700 | 1 | |a Fang, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Haisong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Jianshu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guangcan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Jinliang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced materials (Deerfield Beach, Fla.) |d 1998 |g 36(2024), 11 vom: 01. März, Seite e2307796 |w (DE-627)NLM098206397 |x 1521-4095 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:11 |g day:01 |g month:03 |g pages:e2307796 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/adma.202307796 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 11 |b 01 |c 03 |h e2307796 | ||